Infliximab (Remicade), an intravenous anti-TNF-α monoclonal antibody, has been shown to contribute to the treatment of multiple inflammatory autoimmune diseases, such as IBD, RA, psoriasis, and Kawasaki disease, by specifically binding to and neutralizing TNF-α to inhibit neutrophil recruitment, reducing inflammation and tissue damage.722–724 C5 is a bioactive molecule that activates neutrophils and promotes the release of inflammatory mediators. The gene discussed is TNF; the disease is inflammatory bowel disease.